Literature DB >> 21900022

Extracorporeal membrane oxygenation support improves survival of patients with Hantavirus cardiopulmonary syndrome refractory to medical treatment.

Jorge A Wernly1, Charles A Dietl, Cyril Etta Tabe, Stuart B Pett, Cameron Crandall, Karen Milligan, Mark R Crowley.   

Abstract

OBJECTIVE: The aim of the study was to evaluate the outcome of extracorporeal membrane oxygenation (ECMO) support in Hantavirus cardiopulmonary syndrome (HCPS) patients with a predicted mortality of 100%, and the complications associated with this treatment modality and different cannulation techniques.
METHODS: A total of 51 patients with refractory HCPS were supported with ECMO between April 1994 and June 2010. They were divided into group A consisting of the 26 patients treated between 1994 and 2000 and group B consisting of 25 patients treated between 2003 and 2010. No patients were treated between September 2000 and December 2003. Patients in group A were intubated when they became hypoxic and placed on ECMO when they became hemodynamically unstable, whereas patients in group B had elective insertion of vascular sheaths and were almost concurrently intubated and placed on ECMO when they decompensated. Cannulation of the femoral vessels was performed percutaneously in 18 (35.3%) patients and with an open technique in 33 (64.7%) patients.
RESULTS: Complications from percutaneous cannulation occurred in 4/18 (22.27%) patients: retroperitoneal hematoma in 2/18 (11.1%) and lower-extremity ischemia in 2/18 (11.1%) patients. Complications from open femoral cannulation occurred in 12/33 (36.3%) patients: bleeding in 10/33 (30.3%) patients and ischemia in 2/33 (6.1%) patients. The overall survival was 66.6% (34 of 51 patients); 56% (14/26) for group A and 80% (20/25) for group B (p = 0.048). There was no difference in mortality regarding the method of cannulation. A trend toward increased mortality in patients with cannulation complications was recognized, but it was not statistically significant. Mortality was not associated with ECMO duration (average 121.7h, range: 5-276h). All survivors recovered and were discharged from the hospital after a mean hospital stay of 19.8 days (range: 10-39 days).
CONCLUSIONS: Two-thirds of 51 HCPS patients with a predicted mortality of 100%, who were supported with ECMO, survived and recovered completely. Survival was significantly higher in the second half of the study. Complications associated with both types of femoral cannulation were associated with a trend toward decreased survival, which was not significant.
Copyright © 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21900022     DOI: 10.1016/j.ejcts.2011.01.089

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  18 in total

1.  Extracorporeal membrane oxygenation for the treatment of severe refractory hantavirus cardiopulmonary syndrome.

Authors:  Han Yao; Emily G McDonald
Journal:  CMAJ       Date:  2016-11-28       Impact factor: 8.262

2.  Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration.

Authors:  Guillermo Bugedo; Jorge Florez; Marcela Ferres; Eric Roessler; Alejandro Bruhn
Journal:  Rev Bras Ter Intensiva       Date:  2016-06

Review 3.  The kidney in hantavirus infection-epidemiology, virology, pathophysiology, clinical presentation, diagnosis and management.

Authors:  Felix C Koehler; Veronica Di Cristanziano; Martin R Späth; K Johanna R Hoyer-Allo; Manuel Wanken; Roman-Ulrich Müller; Volker Burst
Journal:  Clin Kidney J       Date:  2022-01-29

4.  A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Authors:  Jay W Hooper; Matthew Josleyn; John Ballantyne; Rebecca Brocato
Journal:  Vaccine       Date:  2013-07-24       Impact factor: 3.641

5.  Host mTORC1 signaling regulates andes virus replication.

Authors:  Shannon McNulty; Mike Flint; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

6.  High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial.

Authors:  Pablo A Vial; Francisca Valdivieso; Marcela Ferres; Raul Riquelme; M Luisa Rioseco; Mario Calvo; Constanza Castillo; Ricardo Díaz; Luis Scholz; Analia Cuiza; Edith Belmar; Carla Hernandez; Jessica Martinez; Sang-Joon Lee; Gregory J Mertz
Journal:  Clin Infect Dis       Date:  2013-06-19       Impact factor: 9.079

Review 7.  Immune response during hantavirus diseases: implications for immunotherapies and vaccine design.

Authors:  Farides Saavedra; Fabián E Díaz; Angello Retamal-Díaz; Camila Covián; Pablo A González; Alexis M Kalergis
Journal:  Immunology       Date:  2021-03-18       Impact factor: 7.215

8.  Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.

Authors:  Virginie Bondu; Ron Schrader; Mary Ann Gawinowicz; Paul McGuire; Daniel A Lawrence; Brian Hjelle; Tione Buranda
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

9.  Varicella associated acute respiratory distress syndrome in an adult patient: an example for extracorporeal respiratory support in Brazilian endemic diseases.

Authors:  Marcela da Silva Mendes; Ho Yeh-Li; Thiago Gomes Romano; Edzangela Vasconcelos Santos; Adriana Sayuri Hirota; Bruna Mitiyo Kono; Marilia Francesconi Felicio; Marcelo Park
Journal:  Rev Bras Ter Intensiva       Date:  2014 Oct-Dec

10.  A High-Throughput Flow Cytometry Screen Identifies Molecules That Inhibit Hantavirus Cell Entry.

Authors:  Tione Buranda; Catherine Gineste; Yang Wu; Virginie Bondu; Dominique Perez; Kaylin R Lake; Bruce S Edwards; Larry A Sklar
Journal:  SLAS Discov       Date:  2018-04-02       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.